3990161

Virus filtration in continuous processing: Impact of low flux on virus retention and mitigation strategy

Date
March 18, 2024
Explore related products in the following collection:

The current generation of parvovirus filters was designed to achieve maximum flux at high feed pressure to minimize batch processing time and filtration area requirements. These virus filters routinely achieve a greater than 5 log reduction value (LRV) within a 2-3 hour batch process. However, continuous processes require these same filters to process the same volumes over multiple days at operating pressures below 10 psi and flux of less than 100 LMH. New data will be presented on the potential reduction in LRV as the flux decreases below the typical batch filtration range. The industry needs to consider the impact of these new operating parameters when integrating virus filtration into continuous processes. A method is introduced here for efficient utilization of virus filters within a continuous process, in which the virus filter is operated intermittently at high flux (thereby ensuring maximum virus retention performance) while also allowing for extended filter changeout time. Experimental data on filter throughput and virus retention performance, covering a multiple day virus filtration run using an intermittent high flux approach, will be presented.

Presenter

Speaker Image for Benjamin Cacace
Principal Engineer, MilliporeSigma

Related Products

Thumbnail for Developing a prophylactic antibody for malaria eradication in low- and middle-income countries (LMICs)
Developing a prophylactic antibody for malaria eradication in low- and middle-income countries (LMICs)
Malaria, a mosquito-transmitted parasitic disease, poses a significant mortality risk globally, especially in Low- and Middle-Income Countries (LMICs)…
Thumbnail for Develop new generation chemically-defined cell culture media: Reduce production cost of therapeutic proteins
Develop new generation chemically-defined cell culture media: Reduce production cost of therapeutic proteins
Cell culture media and process are the key influence factor in the manufacturing cost of biotherapeutics. OPM has developed a new generation chemically-defined CHO media that are proved to work with a variety of CHO clones, like CHO-DG44, CHO-K1, CHO ZN and CHO-S, etc…
Thumbnail for Intensified downstream connected processing of mAbs: PD to scale up for robust, cost effective, and agile manufacturing
Intensified downstream connected processing of mAbs: PD to scale up for robust, cost effective, and agile manufacturing
Connected processing is an intensification strategy where multiple operations are connected and processed in parallel enabling the manufacturer to achieve higher productivity, while keeping time and cost low…
Thumbnail for Democratization of protein-based drug and vaccine supply through regional small-footprint manufacturing
Democratization of protein-based drug and vaccine supply through regional small-footprint manufacturing
Local biomanufacturing capacity could transform access to therapeutics in low- and middle-income countries (LMICs) by promoting self-sufficiency to address current and future needs for biologic drugs and vaccines, ultimately improving both regional livelihoods and health outcomes…